/C O R R E C T I O N -- Seismic Pharmaceuticals/

In the news release, Seismic Pharmaceuticals Announces the Enrollment of the First Patient in the Global Phase 3 Trial of Istaroxime in Cardiogenic Shock, issued 09-Sep-2026 by Seismic Pharmaceuticals over PR Newswire, we are advised by the company that changes have been made. The...